MannKind Corporation representatives at the 10th annual meeting of the Diabetes Technology Society unveiled new data on its drug delivery, device and particle technologies demonstrating the bioequivalence, ease of use and efficiency of the company’s novel platform. The company presented four studies evaluating the proprietary technology, founded on the company’s expertise in inhaled drug development, device engineering and powder formulation performance.
The first application of this technology, the novel, ultra rapid-acting insulin AFREZZA (insulin human [rDNA origin]), is currently under review by the U.S. Food and Drug Administration (FDA) and has a PDUFA date of December 29, 2010.
All presented posters are available on the MannKind website.
